Drugs / HC022
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07306585 | Dec 2025 → Mar 2027 expected | cutaneous lupus erythematosus, systemic lupus erythematosus | HC Biopharma Inc. | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT06657703 | Nov 2024 → Aug 2025 overdue | systemic lupus erythematosus | HC Biopharma Inc. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HC022 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07306585 ↗ |
| Route | Subcutaneous | “single-ascending, subcutaneous (SC) doses of HC022 in healthy subjects” NCT06657703 ↗ |